zilovertamab
merck,oncternal therapeutics
['zilovertamab', 'cll', '$onct']
best small cap bio winner out of #asco22 $onct? very impressive interim ror1 data, especially in p53-mutated mcl cll. landmark pfs over 80% at 15 months for mcl and 100% at 36 months for cll treated w/zilovertamab. ror1 pathway getting further validation in tough population.